Long-term safety study of sevasemten for Becker muscular dystrophy
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This study continues treatment with the investigational drug sevasemten for people with Becker muscular dystrophy who have already been in a previous sevasemten study. The goal is to learn more about the drug's safety and how well it works over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be male and have a diagnosis of Becker muscular dystrophy.
- You must have completed a prior sevasemten study (ARCH, CANYON, GRAND CANYON, or DUNE) within the last few months.
- You must have finished all required visits in that prior study.
- You must not be taking strong or moderate CYP3A4 inhibitors or inducers (medications that affect how the body processes drugs).
- You must not have taken any other investigational drug (besides sevasemten) in the last 30 days or 5 half-lives, whichever is longer.
- You must not have taken oral corticosteroids for Becker muscular dystrophy in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how Becker muscular dystrophy affects the brain and muscles using imaging, thinking tests, and muscle function checks. It aims to learn more about the condition to improve care.
This study follows women who have a confirmed DMD gene mutation (a genetic change related to Duchenne/Becker muscular dystrophy) to learn more about health and muscle-related measurements. Depending on the part of the study, you may be asked to take part in MRI or other assessments.
This study follows people with Duchenne muscular dystrophy (DMD) who are taking eteplirsen, golodirsen, or casimersen. It aims to understand how these medicines work in everyday life over a long period.
This study checks how people with Duchenne muscular dystrophy are doing long-term after receiving delandistrogene moxeparvovec (SRP-9001) in an earlier trial. It helps researchers understand the long-term safety and effects of that treatment.
This study follows people with Duchenne muscular dystrophy who were in an earlier SAT-3247 trial, or who meet certain other criteria, to see how the medicine works over a longer time. It aims to gather more safety and effectiveness information.
This study continues treatment with an investigational medicine called BMN 351 for people with Duchenne muscular dystrophy (a genetic muscle-weakening condition). It checks whether the medicine remains safe and effective when used over a longer period, building on results from an earlier trial.
Hear when a new Becker Muscular Dystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.